PharmaCyte Biotech, Inc.
PMCB
$0.72
-$0.03-3.73%
NASDAQ
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.93M | 3.75M | 3.52M | 3.94M | 4.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.38M | 4.23M | 3.96M | 4.38M | 4.50M |
| Operating Income | -5.38M | -4.23M | -3.96M | -4.38M | -4.50M |
| Income Before Tax | -3.28M | -7.07M | -1.13M | 30.66M | 20.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.28 | -7.07 | -1.13 | 30.66 | 20.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.28M | -7.07M | -1.13M | 30.66M | 20.25M |
| EBIT | -5.38M | -4.23M | -3.96M | -4.38M | -4.50M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.05 | -1.32 | -0.30 | 3.12 | 1.23 |
| Normalized Basic EPS | -1.30 | -1.25 | -0.78 | -0.18 | 0.17 |
| EPS Diluted | -1.05 | -1.32 | -0.30 | 3.12 | 1.23 |
| Normalized Diluted EPS | -1.30 | -1.25 | -0.78 | -0.18 | 0.17 |
| Average Basic Shares Outstanding | 29.71M | 27.41M | 28.25M | 29.32M | 30.81M |
| Average Diluted Shares Outstanding | 29.71M | 27.41M | 28.25M | 29.32M | 30.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -4.96% | -0.87% | -- | -- | -- |